Genocea Biosciences Wins ''Best Vaccine Startup'' Award at World Vaccine Congress 2008
Genocea awarded first ever Vaccine Industry Excellence Award
CAMBRIDGE, Mass. -- Genocea Biosciences, a leading vaccine discovery and development company, today announced it won the “Best Vaccine Startup†award at the largest global vaccine conference, the World Vaccine Congress 2008 in Washington, D.C.
A panel of international judges selected Genocea from over 60 award submissions as the inaugural startup company recipient of the Vaccine Industry Excellence Award (ViE). The ViE Awards have been launched by event organizer Terrapinn to celebrate and recognize excellence and the forward progress of the global vaccines industry. Selection criteria was based on strength of pipeline, quality of investors, reputation of team, and overall technology for companies that have been launched in the past five years.
“This award is a testament to the dedication and vision of our scientific founder Darren Higgins, the tireless efforts of our founding team, and to the world-renowned vaccine industry experts who have joined Genocea,†said Robert Paull, co-founder and President of Genocea Biosciences. “Leaders of some of the most successful vaccine companies, such as Merck Vaccines, Wyeth Vaccines, and CSL Ltd., have validated our technology as an industry-transforming platform. We’re honored and very appreciative of the recognition.â€
Founded in 2006, Genocea Biosciences is focused on identifying antigens for the next generation of novel vaccines. By recreating the human immune system in vitro, Genocea can identify which antigenic epitopes will elicit a competent immune response. Genocea has assembled a world-class team of vaccine experts including George Siber M.D., Former Chief Scientific Officer of Wyeth Vaccines, Adel Mahmoud, M.D., Ph.D., Former President of Merck Vaccines, and Ian Gust, M.D., Former Director of Research at CSL Ltd.
About Genocea Biosciences:
Genocea Biosciences is commercializing key breakthroughs in vaccine discovery and development. Genocea can rapidly identify antigens that result in the in vivo stimulation of protective CD8+ and CD4+ T cells, targets that can be immediately incorporated into existing antigen delivery systems to produce multivalent vaccine formulations that have the highest probability of generating protective cell-mediated immunity. Genocea is currently developing vaccines for disease such as chlamydia trachomatis. Visit www.genocea.com for more information.